Sqz Biotechnologies Co Performance
| SQZDelisted Stock | USD 0.10 0.04 28.57% |
The entity has a beta of -1.63, which indicates a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Sqz Biotechnologies are expected to decrease by larger amounts. On the other hand, during market turmoil, Sqz Biotechnologies is expected to outperform it. Sqz Biotechnologies right now has a risk of 0.0%. Please validate Sqz Biotechnologies daily balance of power, as well as the relationship between the day typical price and period momentum indicator , to decide if Sqz Biotechnologies will be following its existing price patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Sqz Biotechnologies Co has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong basic indicators, Sqz Biotechnologies is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors. ...more
| Begin Period Cash Flow | 145.8 M | |
| Total Cashflows From Investing Activities | -488 K |
Sqz |
Sqz Biotechnologies Relative Risk vs. Return Landscape
If you would invest 10.00 in Sqz Biotechnologies Co on August 27, 2024 and sell it today you would earn a total of 0.00 from holding Sqz Biotechnologies Co or generate 0.0% return on investment over 90 days. Sqz Biotechnologies Co is generating negative expected returns assuming volatility of 0.0% on return distribution over 90 days investment horizon. In other words, 0% of stocks are less volatile than Sqz, and above 99% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
Sqz Biotechnologies Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Sqz Biotechnologies' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Sqz Biotechnologies Co, and traders can use it to determine the average amount a Sqz Biotechnologies' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| SQZ |
Based on monthly moving average Sqz Biotechnologies is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Sqz Biotechnologies by adding Sqz Biotechnologies to a well-diversified portfolio.
Sqz Biotechnologies Fundamentals Growth
Sqz Stock prices reflect investors' perceptions of the future prospects and financial health of Sqz Biotechnologies, and Sqz Biotechnologies fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Sqz Stock performance.
| Return On Equity | -1.05 | |||
| Return On Asset | -0.33 | |||
| Operating Margin | (3.92) % | |||
| Current Valuation | (6.5 M) | |||
| Shares Outstanding | 29.49 M | |||
| Price To Book | 0.50 X | |||
| Price To Sales | 1.24 X | |||
| Revenue | 21.03 M | |||
| EBITDA | (59.28 M) | |||
| Cash And Equivalents | 63.71 M | |||
| Cash Per Share | 3.61 X | |||
| Total Debt | 27.47 M | |||
| Debt To Equity | 0.74 % | |||
| Book Value Per Share | 1.36 X | |||
| Cash Flow From Operations | (83.55 M) | |||
| Earnings Per Share | (2.16) X | |||
| Total Asset | 99.9 M | |||
| Retained Earnings | (274.97 M) | |||
About Sqz Biotechnologies Performance
Evaluating Sqz Biotechnologies' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Sqz Biotechnologies has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Sqz Biotechnologies has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. SQZ Biotechnologies Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts. Sqz Biotechnologies operates under Biotechnology classification in the United States and is traded on New York Stock Exchange. It employs 113 people.Things to note about Sqz Biotechnologies performance evaluation
Checking the ongoing alerts about Sqz Biotechnologies for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Sqz Biotechnologies help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Sqz Biotechnologies is not yet fully synchronised with the market data | |
| Sqz Biotechnologies has some characteristics of a very speculative penny stock | |
| Sqz Biotechnologies has a very high chance of going through financial distress in the upcoming years | |
| The company reported the last year's revenue of 21.03 M. Reported Net Loss for the year was (79.46 M) with loss before taxes, overhead, and interest of (43.05 M). | |
| Sqz Biotechnologies Co has about 63.71 M in cash with (83.55 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.61, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 67.0% of the company shares are owned by institutional investors |
- Analyzing Sqz Biotechnologies' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Sqz Biotechnologies' stock is overvalued or undervalued compared to its peers.
- Examining Sqz Biotechnologies' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Sqz Biotechnologies' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Sqz Biotechnologies' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Sqz Biotechnologies' stock. These opinions can provide insight into Sqz Biotechnologies' potential for growth and whether the stock is currently undervalued or overvalued.
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in producer price index. You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Other Consideration for investing in Sqz Stock
If you are still planning to invest in Sqz Biotechnologies check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Sqz Biotechnologies' history and understand the potential risks before investing.
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |